Lycera isa preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. Lyceraâ€™s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.
Funding Rounds (4) - $74.89MUpdate
Current Team (7)Update
|Jun 22, 2016||Xconomy - Atlas, Novartis Put $27M Into IFM to Battle Cancer, Autoimmune Diseases|
|May 25, 2016||PRNewswire UK All - Pharming Reports on Annual General Meeting of Shareholders Pharming's Board of Supervisory Directors Announce Paul Sekhri as New Chairman|
|Apr 13, 2016||PE HUB - Versant Ventures makes Davis an MD|
|Feb 8, 2016||Business Wire - Regeneron, Cellectis, Flagship Ventures and others headline NewYorkBIO 2016 CEO Breakfast Club Series|
|Oct 6, 2015||PRNewswire All - Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting|
|Jul 23, 2015||Business Wire - Celgene Reports Second Quarter 2015 Operating and Financial Results|
|Jul 13, 2015||Business Wire - Distinguished Pharma Leaders and Experienced Investors Join Together in Nuvelution Pharma, Inc.|
|Jun 11, 2015||Xconomy - Lycera’s End Game? $104M Celgene Deal Could Lead to Buyout|
2800 Plymouth Rd.
NCRC, Building 26
Ann Arbor, MI 48109